Top Oligonucleotide Synthesis Companies

Global Oligonucleotide Synthesis Market size was valued at USD 7.30 Billion in 2024 and is poised to grow from USD 8.57 Billion in 2025 to USD 30.93 Billion by 2033, growing at a CAGR of 17.4% during the forecast period (2026–2033).

Investing in the development of oligonucleotide synthesis for different disease indications should remain the prime focus of all companies. Reducing the costs of synthesis will be a major area of interest for all oligonucleotide synthesis providers to improve their profitability. Utilizing supportive government initiatives and funding to maximize R&D scope will also be a popular strategy for oligonucleotide synthesis market players in the future.  'Thermo Fisher Scientific (USA)', 'Merck KGaA (Germany) ', 'Agilent Technologies (USA) ', 'LGC Biosearch Technologies (UK) ', 'Integrated DNA Technologies (IDT) (USA) ', 'Eurofins Genomics (Luxembourg) ', 'GenScript Biotech Corporation (USA) ', 'Twist Bioscience (USA) ', 'Bio-Synthesis Inc. (USA) ', 'ATUM (USA) ', 'DNA Script (France) ', 'SGI-DNA (USA) ', 'Eurogentec (Kaneka) (Belgium) ', 'Creative Biogene (USA) ', 'GeneCust Europe (Luxembourg) ', 'Synbio Technologies (USA) ', 'Epoch Life Science, Inc. (USA) ', 'Bioneer Corporation (South Korea) ', 'Genewiz (Azenta Life Sciences) (USA)'

Oligonucleotides play a key role in diagnostic tools such as PCR, qPCR, and next-generation sequencing (NGS) and demand for early diagnostics is increasing rapidly. This factor is projected to create new opportunities for oligonucleotide synthesis market growth going forward. 

Use of AI and Automation: Automation and artificial intelligence are being integrated into oligonucleotide synthesis processes, to enhance the accuracy and scalability of the process. Automated synthesizers and AI-driven design tools are projected to be highly popular as they can assist in cost reduction as well.

North America is projected to account for a dominant oligonucleotide synthesis market share. The presence of a strong medical research infrastructure, supportive government funding for research, and rising use of genetic treatments are helping this region maintain its high market share. The United States and Canada are estimated to be the leading markets in this region as incidence of chronic diseases rises in these countries. The presence of leading pharmaceutical and biotechnology companies will also promote the demand for oligonucleotide synthesis in this region.